Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
BUX Stock Chart & Stats
C$0.46
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.46
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.20 - C$0.58
Previous CloseN/A
Volume0.00
Average Volume (3M)16.46K
Market Cap
C$55.70M
Enterprise ValueC$59.33M
Total Cash (Recent Filing)C$1.55M
Total Debt (Recent Filing)C$153.22K
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding105,090,210
10 Day Avg. Volume19,330
30 Day Avg. Volume16,464
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)-41.95
Price to Sales (P/S)156.67
P/FCF Ratio-25.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityLow debt relative to equity reduces solvency risk and preserves strategic optionality for R&D and commercialization spending. This capital structure gives management time to execute development milestones or raise capital under less pressured terms versus a highly leveraged peer.
Business Focus On Diagnostics With Structural DemandThe company operates in oncology diagnostics — a durable, growing market driven by aging populations and emphasis on early detection. A clear product focus on blood-based assays supports scalable unit economics and repeated clinical use if assays gain clinical adoption and reimbursement.
Gross Margin Foundation And Historical Revenue GainsA near-30% gross margin provides a base to leverage fixed R&D and commercial costs as sales scale. Historical multi-year revenue improvement versus earlier years indicates some product/market traction, suggesting upside if the firm stabilizes sales and reduces operating losses.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the business cannot self-fund near-term operations. Continued cash burn forces recurrent external financing, increasing dilution risk and constraining investment in clinical validation, commercialization, and hiring needed to scale.
Declining Recent Revenue And Deeply Negative MarginsA meaningful recent revenue decline combined with extreme negative net margins signals fragile commercial momentum and operating cost structures misaligned with current sales. This undermines a clear, near-term path to breakeven and increases pressure on strategy execution.
Small Scale And Equity VolatilityA small revenue base and volatile/negative equity amplify execution and financing risk. Limited scale reduces bargaining power with partners and payers, while past equity volatility raises likelihood of future capital raises and shareholder dilution, hampering long-term value creation.
BioMark Diagnostics News
BUX FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was C$0.20 and its highest was C$0.58 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is C$55.70M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Mar 03, 2026 which is in 8 days.
How were BioMark Diagnostics’s earnings last quarter?
BioMark Diagnostics released its earnings results on Nov 29, 2025. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 105,090,210 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
BioMark Diagnostics reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.448%.
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in TSE:BUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioMark Diagnostics
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Technical Analysis
Spectral Medical
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
ZYUS Life Sciences
―
Sona Nanotech Inc
―
Options Prices
Currently, No data available
---